Stabilization period [Design Issues]

posted by Vismayi – India, 2023-06-26 21:55 (686 d 19:20 ago) – Posting: # 23614
Views: 2,867

Good morning to one and all,

This is regarding patient PK study, we have upcoming study.

Indication: Ovary cancer

In this study,we need to stabilize patients but for how many days neither it is mentioned in specific guidance nor product leaflet. So, what duration we should we consider for stabilization.

Beside,study product can be taken until patient tolerate as per leaflet.


If the disease pre-valence is less and this may lead to challenge in recruitment. So can we consider replicate design over conventional two-way.


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
80 visitors (0 registered, 80 guests [including 47 identified bots]).
Forum time: 17:15 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5